Kornimate/medical-research-clean huggingface dataset:
effects of sulforaphane for patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: patients with chronic kidney disease (ckd) have many complications associated with inflammation, oxidative stress and intestinal dysbiosis, which are closely related to the progression of kidney failure and cardiovascular disease. sulforaphane, an isothiocyanate found in cruciferous vegetables (family: brassicaceae) is recognized as one of the most important activators of erythroid nuclear factor 2 related to factor 2 (nrf2). however, clinical evidence to assess the effects of sulforaphane in patients with ckd is scarce, and there are no studies that have investigated its effects on the expression of genes and markers related to inflammation in these patients. thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of sulforaphane on transcription factors and inflammatory markers in patients with ckd.

this is a longitudinal, randomized, crossover study with patients with ckd on hemodialysis and in non-dialysis patients. both groups will receive 4g of sulforaphane per day for 2 months and the placebo group will receive 4g of corn starch colored with chlorophyll for 2 months. peripheral blood mononuclear cells (pbmc) are being isolated for expression of nrf2, nf-kb, and nadph quinone oxidoreductase 1 (nqo1), ho-1, vcam-1, e-selectin, nlrp3, il-1b, il 18, pgc1-α, sentrins, nrf2, nrf-1 e tfam mrna expression by a quantitative real-time polymerase chain reaction. antioxidant enzymes activity (catalase-cat and glutathione peroxidase-gpx), high-sensitivity c-reactive protein (hs-crp) will be assessed using an enzyme-linked immunosorbent assay (elisa).the serum concentration of other cytokines and growth factors will be detected by means of a multiparametric immunoassay based on magnetic microspheres marked with xmap (luminex corp, usa) before and after supplementation.

Eligibility criteria:
criteria inclusion criteria: * aged 18 to 75 years * clinical diagnosis of chronic kidney disease * conservative treatment group: ckd stages 3 and 5 receiving nutritional treatment for at least 6 months * hemodialysis group: hemodialysis patients for more than 6 months exclusion criteria: * patients pregnant * smokers * using antibiotics in the last 3 months * autoimmune diseases * clinical diagnosis of infectious diseases * clinical diagnosis of cancer * clinical diagnosis of aids
quantitative sensory testing in subjects with sensitive skin or not

Conditions: Sensitive Skin

Summary: sensitive skin is a common problem, with 50% of women and 30% of men in europe feel they have sensitive skin. the quantitative sensory testing (qst) is a physico-psychic method that uses gradients stimuli of different modalities to measure a subjective somatosensory response. this allows to characterize sensory dysfunction by assessing the participation of small and large nerve fibers. the aim of this project is to characterize the presence or absence of a neurological disorder in patients with sensitive skin. this discovery would be a decisive argument to reinforce the suspicion that sensitive skins is linked to a small fiber neuropathy.

sensitive skin is a common problem, with 50% of women and 30% of men in europe feel they have sensitive skin. a sensitive skin is characterized by the occurrence of tingling sensations, tightness, heat, burning, itching or pain triggered by non pathogenic factors such as wind, heat, cold, water , cosmetics, toiletries, stress... the quantitative sensory testing (qst) is a physico-psychic method that uses gradients stimuli of different modalities to measure a subjective somatosensory response. this allows to characterize sensory dysfunction by assessing the participation of small and large nerve fibers. the aim of this project is to characterize the presence or absence of a neurological disorder in patients with sensitive skin. this discovery would be a decisive argument to reinforce the suspicion that sensitive skins is linked to a small fiber neuropathy.

Eligibility criteria:
inclusion criteria: * age: between 20 and 60 years * cooperating patient * informed and written consent of the subject * affiliated to the social security * for subjects with sensitive skin: subjects with a score greater than 50 on the scale sensitive scale - to control subjects: subjects with result of less than 20 sensitive to the scale scale exclusion criteria: * adults subject with legal protection * subject in a social institution. * subject with major cognitive or psychiatric disorders * subject with pathological use of alcohol or consumption of another drug. * subject with skin involvement of the back of the dominant hand or malformation. * known sensitive neuropathy * pregnant woman * subject receiving medical treatment which may interfere with the results. * subject with treatment in the back of the dominant hand.

Keywords: sensitive skin quantitative sensory testing
polymorphisms of fibrosis-relating genes on outcome of hcv-related chronic liver disease

Conditions: Fibrosis; Chronic Liver Disease

Summary: hepatitis c virus (hcv) infection causes different disease spectrum ranging from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma. evidence indicates that host genetic factor may play a role in determining disease progression. it is known that many cytokine polymorphisms affect disease progressin via increasing hepatic fibrosis that are key factors in progressing liver injury. by combinations of fibrosis-relating gene polymorphisms, this study aims to identify patients with high risk for progressive liver disease. these patients need intensive therapy to decrease morbidity and mortality of chronic hcv-related liver disease.

determination of the following fibrosis-relating gene polymorphisms in hcv-related chronic liver disease and hcc will be performed: tnf-α , tnf-β, factor v leiden, tgf-β1, pdgf-b gene, angiotensinogen (at),angiotensin converting enzyme (ace), microsomal epoxide hydrolase (meh) and glutathione-s-transferase (gst).

Eligibility criteria:
inclusion criteria: * patients with anti-hcv positive exclusion criteria: * anti-hcv-negative patients

Keywords: hepatitis c virus infection chronic liver disease fibrosis-related cytokine
a study to evaluate the safety and efficacy of abt-493/abt-530 in adult post-liver or post-renal transplant recipients with chronic hepatitis c virus (magellan-2)

Conditions: Chronic Hepatitis C; HCV; Hepatitis C Virus

Summary: the purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of abt-493/abt-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis c virus (hcv) infection.


Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age at time of screening. * screening laboratory result indicating hepatitis c virus (hcv) genotype 1-6 (gt1-6) infection. * subject is a recipient of a cadaveric or living donor liver transplant which was a consequence of hcv infection at least 3 months prior to screening or subject received a cadaveric or living donor kidney at least 3 months before screening. * subjects must be documented as non-cirrhotic. * subject is currently taking a stable immunosuppression regimen based on tacrolimus, sirolimus, everolimus, mycophenolate mofetil (mmf), mycophenolic acid, azathioprine, and/or cyclosporine. exclusion criteria: * female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug. * clinical history of fibrosing cholestatic hepatitis post-transplant. * re-transplantation of the liver or kidney. * steroid resistant rejection of the transplanted liver or kidney, or a history of rejection treated with high dose steroid within 3 months of screening. * history of post-transplant complications related to hepatic or renal vasculature.

Keywords: hcv treatment experienced hepatitis c hcv genotype 3 without cirrhosis non-cirrhotic hcv genotype 2 renal transplant hcv treatment naive post transplant hcv genotype 6 liver transplant hcv genotype 5 hcv genotype 4 kidney transplant hcv genotype 1
yoga in improving quality of life in patients with non-small cell lung cancer undergoing treatment

Conditions: Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Carcinoma

Summary: the purpose of this research study is to evaluate the effects of yoga (including breathing exercises) on the quality of life in patients, diagnosed and undergoing standard treatments for non-small cell lung cancer.

this clinical trial studies yoga in improving quality of life in patients with non-small cell lung cancer undergoing treatment. yoga may help improve quality of life and pulmonary functional capacity in patients with non-small cell lung cancer.

Eligibility criteria:
inclusion criteria: * patients with any type of non-small cell lung cancer who are undergoing medical treatment, including surgery, radiation and / or chemotherapy. exclusion criteria: * metastasis to the brain, problems during surgery leading to myocardial infarction or hemorrhage, cerebral infarction or hemorrhage, respiratory failure, non-healing surgical wound.

Keywords: stage ia non-small cell lung carcinoma stage ib non-small cell lung carcinoma stage iia non-small cell lung carcinoma stage iib non-small cell lung carcinoma stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
develop a novel occupational training program for schizophrenia patients based on virtual reality techniques

Conditions: Schizophrenia; Cognitive Impairment

Summary: establish a novel vocational training program and test its validity in a pilot study.

40 schizophrenia patients will be recruited to join the virtual reality based vocational training program, the training effect will be compared by interview skills and problem solving before and after the training.

Eligibility criteria:
inclusion criteria: * having a diagnosis of schizophrenia based on the diagnostic and statistical manual of mental disorders -5th version * aged between 20 and 55 years. * motivated to have a job. * having a full-scale iq \> 70 on the wechsler adult intelligence scale-version iv. * having a panss positive scale \< 70, indicating a stable condition during the illness course. exclusion criteria: * comorbid with other major psychiatric disorders (i.e., bipolar disorders) or neurological diseases. * substance abuse within one year. * visual impairment and/or hearing impairment that would preclude participation in the vr-based training program.
immunoadsorption in patients with severe systemic sclerosis

Conditions: Systemic Scleroderma

Summary: the purpose of this study is to evaluate source data for the survival and the investigation of the preliminary efficacy of immunoadsorption in patients with severe systemic sclerosis.


Eligibility criteria:
inclusion criteria: * systemic sclerosis according to the ace-criteria * severe pulmonary manifestation with reduced dlco * signed informed consent exclusion criteria: * inadequate peripheral venous access * participation in another clinical trial * heart failure * pronounced allergic diathesis, particularly in case of known hypersensitivity to drugs and/or materials used in the extracorporeal circuit
multivariable recovery after exercise-induced muscle pain in the forearm muscles

Conditions: Musculoskeletal Pain; Healthy; Delayed Onset Muscle Soreness

Summary: this study investigates the evolution of sensory, motor and tissue variables following exercise-induced pain in wrist extensor muscles in healthy subjects.

the aim of this study is to determine how is the normalization process of sensory (pressure pain thresholds, subjective pain sensation, self-recovery perception), motor (maximal isometric strength, active range of motion, manual dexterity) and tissue (myotonometer) variables after an experimental pain model in the extensor forearms muscles, by delayed onset muscle soreness after an eccentric exercise in healthy subjects. this way will be possible to establish 1) if there are differences in the time of normalization for each variable; 2) if there is a correlation between each variable and self-recovery perception. seven assessment sessions are performed in a 14-days period. day 0 (baseline assessment 1), day 7 (baseline assessment 2, pre exercise), day 7 (post exercise), day 8 (24-hours post exercise), day 9 (48-hours post exercise), day 10 (72-hours post exercise), day 14 (1-week post exercise).

Eligibility criteria:
inclusion criteria: * adult healthy subjects of both sexes. * age: 18-50. * being free from any pain specific to the upper limb and/or in general. exclusion criteria: * history of acute or chronic painful condition in the previous 3 months. * regular medication intake for any reason. * history of severe injury in the upper extremity (e.i. fracture). * prior surgery in the upper limb. * diagnosed of any chronic pain syndrome (fibromyalgia, migraine, etc.) or severe disease. withdrawal criteria: * being involved in new physical stimulus, which volunteer is not used to. * micronutrient supplementation intake. * nsaids or other medication intake.

Keywords: musculoskeletal pain delayed onset muscle soreness pain mechanisms pressure pain threshold myotonometer maximal isometric strength manual dexterity
prevalence & progression of subclinical atherosclerosis

Conditions: Atherosclerosis; Cardiovascular Diseases; Coronary Arteriosclerosis; Carotid Artery Diseases; Menopause

Summary: to evaluate subclinical atherosclerotic disease in menopausal women.

background: decreased ovarian function and premenopausal obesity are likely the primary determinants of early coronary atherosclerosis as measured by calcification on ebct. aortic calcification occurs earlier than coronary calcification, may predict coronary calcification, and is expected to be the best marker of risk associated with traditional factors in these younger women. preliminary data indicate that changes in coronary and aortic calcification can be observed over short periods of time in these women. a period of diminishing estrogen levels is the optimum time to observe changes in endothelial function which likely precede measurable atherosclerosis and thus may be the earliest markers for disease potential. vascular stiffness, a marker for the biologic aging of the vascular system, is highly correlated with measures of insulin sensitivity which is altered in women at mid-life in conjunction with increases in central adiposity. racial differences in disease prevalence and the relative importance of certain risk factors are likely. design narrative: subclinical atherosclerosis will be evaluated in 728 women (305 african american, 423 caucasian) enrolled in the pittsburgh and chicago sites of the study of women's health across the nation (swan), a multicenter study characterizing the biological and psychosocial antecedents and sequellae of menopause. the extent to which diminishing ovarian function affects vascular function and accelerates the development of atherosclerosis in the coronary arteries, aorta and carotid arteries will be evaluated. serial measures of coronary and aortic calcification (by electron beam computed tomography \[ebct\] ), carotid atherosclerosis, endothelial function and aortic stiffening will be performed two years apart. the prevalence and progression of subclinical atherosclerosis will be evaluated in relation to serial measures of ovarian function, psychosocial and behavioral factors, markers of clotting and inflammation as well as traditional cardiovascular risk factors, all collected in swan. the study is conducted jointly by dr. lynda powell (r01hl65581) at rush-presbyterian-st. luke's medical center in chicago and dr. kim tyrrell (r01hl65591) at the university of pittsburgh.

Eligibility criteria:
no eligibility criteria
the efficacy of emla cream vs. synera patch for pain reduction during venipuncture in children

Conditions: Pain; Needle Phobia

Summary: this study compares the efficacy of the synera patch with eutectic mixture of local anesthetics (emla) as a topical anesthetic for venipuncture in pediatric patients.

venipunctures are common and necessary components of pediatric health care. unfortunately, many children have "needle phobia" and even a simple procedure, such as a venipuncture, can cause significant stress and anxiety to the patient and the parents involved. studies have shown that needles are the worst part of hospital/healthcare related visits for children. the synera patch uses a controlled heating system to transcutaneously deliver a lidocaine/tetracaine mixture for analgesic effect. no published studies compare the efficacy of the synera patch with other topical anesthetics in children. the objective of this study is to compare the efficacy of the synera patch applied for 20 minutes with the efficacy of emla cream applied for 60 minutes in reducing pain associated with venipunctures in children. patients, 4-12 years old children requiring venipunctures in clinics, were randomized to receive synera for 20 minutes or emla for 60 minutes. a blinded observer recorded pain scores using a numerical rating scale (nrs). child and parent assessed pain with the wong-baker faces scale and the nrs, respectively. the primary outcome was the number of subjects reporting "no pain". secondary outcomes were parent and observer measures of the child's pain and the presence of skin reactions.

Eligibility criteria:
inclusion criteria: * children in outpatient clinics requiring venipuncture for medical care * ages 4-12 years old * the ability to demonstrate proper understanding of the wong-baker faces pain ranking scale * parents of enrolled children need to be present during the procedure and be willing to rate their child's pain exclusion criteria: * damaged or inflamed skin at the designated application site * known sensitivity to components of synera or emla (lidocaine, tetracaine, or local anesthetics of the amide or ester type, para aminobenzoic (paba) derivatives) * contraindications to synera or emla use (severe hepatic disease, history of drug-induced methemoglobinemia, taking class 1 antiarrhythmics) * use of analgesics during the past 24 hours

Keywords: emla venipuncture children synera patch pediatric lidocaine/prilocaine
a study of the effect of mk-8457 on blood pressure in hypertensive participants (mk-8457-004-am1)

Conditions: Hypertension

Summary: this study will evaluate the effect of treatment with multiple doses of mk-8457 on systolic blood pressure in participants with mild to moderate hypertension in addition to safety and tolerability. the study hypothesis is that mk-8457 does not increase systolic blood pressure to a clinically significant extent, as measured by 24-hour mean ambulatory systolic blood pressure change from baseline after 10 days of dosing.


Eligibility criteria:
inclusion criteria: * if female, must be of non-childbearing potential * if male with female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study and for 90 days after the last dose of study drug * body mass index (bmi) ≤35 kg/m\^2 * mild-to-moderate hypertension requiring treatment with one or more antihypertensive agents * receiving stable treatment for hypertension for at least 8 weeks prior to the start of dosing and continuing therapy for duration of study * no clinically significant arrhythmias or clinically significant abnormality on electrocardiogram * nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months exclusion criteria: * any illness that might confound the results of the study or poses an additional risk * history of stroke, chronic seizures, or major neurological disorder * clinically significant endocrine, gastrointestinal, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * clinically significant cardiovascular disease or has active angina * history of malignant neoplastic disease * taking 325 mg aspirin daily * taking 3 or more medications for the treatment of hypertension * unable to refrain from or anticipates the use of any non-steroidal anti-inflammatory drugs (nsaids) * consumes excessive amounts of alcohol and/or coffee, tea, cola, or other caffeinated beverages * has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks * significant multiple and/or severe allergies * regular user of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years
changes in functional performance in individuals with parkinson's disease following 2-month physiotherapy intervention

Conditions: Parkinson Disease

Summary: aim of current study was to evaluate the effect of a 2-month comprehensive physiotherapy intervention on different aspects of functional performance. in addition, progression of pd motor symptoms (using standardized clinical tests for the assesment) was of interest

the aim of current study was to enroll 50 patients with parkinson's disease (pd) and randomly assign them into intervention and control group. patients were randomly contacted through the epidemiological database of patients with parkinson' disease of south-estonia. 44 participants agreed to come to the baseline assessment including: * timed-up-and-go test battery * four square step test * physical performance test * short physical performance * 10-m walk test * grooved purdue pegboard test * assessment of range of motion in addition, current disease status was assessed using unified parkinson disease rating scale, mini mental sate examination. further, quality of life was assessed using pdq-39, hand-writing was recorded using white, squared and striped paper and freezing of gait questionaire (fog-q) was administered. within a week from baseline assessment participants randomly assigned to intervention group, started physiotherapy intervention. the intervention was carried out in small groups (3 people in a group) and was carried out as out-patient physiotherapy during 8 week period. during each week 2 sessions with a length of an hour were scheduled. within a week of the last therapy session, second assessment was conducted (for control group the second assessment was carried out ten weeks post-baseline assessment. third assessment was assigned one year after (then the same assessment was performed, in addition body composition was analysed using dxa), forth assessment an other year later. during forth assessment 15 members starting in the intervention group and 10 starting in the control group participated.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of idiopathic parkinson disease 2. age within the age limits 3. no other untreated medical conditions that might affect gait or postural stability 4. able to walk without assistive device 5. score of mini mental state examination above 24 6. no other neurological conditions in medical anamnesis exclusion criteria: not meeting the inclusion criteria

Keywords: parkinson disease gait physical therapy functional performance group therapy